A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer

BACKGROUND: Previously, we conducted the 5-year open-label, randomized controlled trial (RCT) of leuprorelin adjuvant therapy in post-operative premenopausal patients with endocrine-responsive breast cancer, which was a pilot study to investigate the optimal duration of leuprorelin treatment. Since,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurebayashi, Junichi, Shiba, Eiichi, Toyama, Tatsuya, Matsumoto, Hiroshi, Okazaki, Minoru, Nomizu, Tadashi, Ohtake, Tohru, Fujii, Takaaki, Ohashi, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064970/
https://www.ncbi.nlm.nih.gov/pubmed/33638810
http://dx.doi.org/10.1007/s12282-020-01205-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064970/
https://www.ncbi.nlm.nih.gov/pubmed/33638810
http://dx.doi.org/10.1007/s12282-020-01205-w

Ejemplares similares